FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy
Related Topics >> Novo Nordisk | Eli Lilly | Diabetes | Byetta | Amylin

Novo drug bests Byetta in ADA study

Tools

Amylin Pharmaceuticals' stock is suffering from a Novo Nordisk study that showed its experimental diabetes drug liraglutide outperformed Amylin's flagship drug Byetta, co-developed with Eli Lilly; shares dropped more than 8 percent Friday to close at $29.93. Report

More stories about Novo Nordisk   Eli Lilly   Diabetes   Byetta   Amylin  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 78 + 16?
To combat spam, please solve the math question above.